We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ask ADVFN Intelligence (AI)
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc PR Newswire PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 ● Acquisition positions Chiesi to expand patient access to...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic...
By Colin Kellaher Amryt Pharma PLC on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to Mycapssa for the treatment of carcinoid syndrome, the most common...
By Colin Kellaher Amryt Pharma PLC plans to pursue a formal dispute resolution with the U.S. Food and Drug Administration over the agency's rejection of the biopharmaceutical company's...
By Colin Kellaher Shares of Amryt Pharma PLC fell more than 30% on Monday after the biopharmaceutical company said the U.S. Food and Drug Administration turned away its application seeking...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc. PR Newswire NEW YORK, May 5, 2021 NEW YORK, May 5, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential...
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...
AMRYT REPORTS RECORD Q3 2020 RESULTS 19% YoY revenue growth in the quarter to $49.3M Raising full year revenue guidance to $180M - $182M Both metreleptin and lomitapide driving revenue performance...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
